1. In the present study, we sought to determine whether patients with restenosis after coronary stenting possess increased monocyte reactivity, as manifested by a higher level of adhesion molecule expression and an enhanced propensity to form monocyte-platelet aggregates after activation in vitro.
INTRODUCTION
Percutaneous transluminal coronary angioplasty (PTCA) has found widespread application in the management of coronary artery disease (CAD). With improvements in techniques and tools, more complex lesions are being treated. Unfortunately, restenosis continues to limit the long-term success of the procedure, resulting in the need for repeat revascularization in approximately 30% of patients. 1 The pathogenesis of restenosis is not completely understood. Two principal mechanisms, namely excessive neointimal growth and negative remodelling, have been proposed to contribute towards restenosis. 2 The failure of stenting to considerably improve the prognosis and the high incidence of late in-stent restenosis suggests that neointimal thickening plays a leading role. 3, 4 Emerging experimental and clinical data indicate that inflammation triggers neointimal formation and, thus, restenosis. Immunohistochemical analysis has revealed that inflammatory cells (monocytes/macrophages) are prevalent in human restenotic lesions and comprise substantial lesion volume. 5, 6 Moreover, PTCA-induced appearance of activated leucocytes (monocytes and granulocytes) and leucocyte-platelet aggregates in blood, [7] [8] [9] as well as elevated plasma concentrations of monocyte-related cytokine interleukin (IL)-6, 10 have been observed to correlate with later clinical outcome.
In animal models of balloon angioplasty and stenting, it was shown that monocytes are recruited early and abundantly to the denuded vessels and, by producing bioactive mediators, stimulate smooth muscle cell migration and proliferation leading to neointimal hyperplasia. 11 A strong correlation between the extent of inflammatory reaction, characterized by mononuclear cell infiltration, and late neointimal thickening was found. 12 In addition, blockade of MCP-1 (monocyte chemoattractant protein-1) 13 and integrins VLA-4 14 (CD49d/CD29) and Mac-1 15 (CD11b/CD18), molecules responsible for leucocyte recruitment to the damaged area, or infusion of IL-10, a potent monocyte deactivator, 16 were effective in the attenuation of experimental restenosis.
The above evidence that monocytes may be central promoters of neointimal hyperplasia after vascular injury prompted us to question whether patients with restenosis may exhibit elevated leucocyte reactivity after activation in vitro. We have analysed the expression of several monocyte antigens that can participate in cell adhesion and inflammatory reactions in patients with and without restenosis after stenting. Our results demonstrate that monocyte expression of the integrins Mac-1 and VLA-4 and the number of monocyte-platelet complexes after activation in whole blood are significantly higher in patients with angiographically verified restenosis.
METHODS

Patients
For this pilot study, we enrolled 24 patients who were to undergo coronary angioplasty due to stable coronary artery disease and follow-up angiography. The study was approved by the Hospital Ethics Board of the Cardiology Research Center of Ministry of Health (Moscow, Russia) and subjects gave informed consent to participate in the study. The inclusion criteria were successful PTCA with stenting of a single lesion in a native coronary artery. Exclusion criteria included recent (< 2 weeks before the procedure) myocardial infarction, bypass graft lesions and concurrent illnesses (cancer or chronic inflammatory diseases). Coronary angioplasty with insertion of metallic stents of the same design was performed according to standard techniques by two operators (ANS and SIP). The procedure was considered successful when the residual diameter stenosis immediately after the procedure was < 10% and if no major complications occurred (in-hospital death, urgent bypass surgery, redo-PTCA, myocardial infarction). All patients received the same medications (aspirin 125 mg/day, beta-blockers and hypolipidaemic agents) before PTCA and during the follow-up period. Conventional treatment, including nitroglycerin (250 g) and heparin (10 000 U), was administered during PTCA, heparin was infused at 500-1000 U/h during the 12 h after stenting and 500 mg/day ticlopidin was administered for 1 month after PTCA.
Quantitative coronary angiography
All cineangiograms were analysed with the Quantitative Coronary Analysis system (HICOR; Siemens, Berlin, Germany), as described previously. 17 Angiographic analyses were performed on angiograms obtained before and after stenting and at a 6 month follow-up period (earlier if clinically indicated) and the average of multiple matched views with orthogonal projections were used whenever possible.
Laboratory measurements
Blood samples were obtained 6 months after stenting. Using sodium citrate as an anticoagulant, blood was drawn from the antecubital vein, with minimal tourniquet pressure, between 0900 and 1000 h. Samples were stored on ice for 1 h and then incubated with 1 g/mL lipopolysaccharide (LPS) at 37°C for 2 h. For analysis of the dynamics of surface antigen expression and monocyte-platelet aggregation, blood withdrawn from patients was divided into 0.5 mL aliquots for either: (i) immediate fixation; (ii) 60 min storage on ice before fixation; and (iii) 30, 60, 120 and 240 min treatment with LPS at 37°C before fixation. Fixation of blood aliquots was with 0.5% paraformaldehyde (PF) for 10 min at room temperature, its purpose being to prevent subsequent changes in cell surface antigen expression and dissociation of monocyte-platelet complexes. Erythrocytes were then lysed in HEPES buffer containing 0.155 mol/L ammonium chloride, pH 7.3, for 10 min at room temperature and, thereafter, leucocytes were washed and resuspended in phosphate buffer containing 0.1% bovine serum albumin. Cellular surface antigen expression was measured by standard direct immunofluorescence flow cytometry. The following monoclonal antibodies (mAbs; all from Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) were used: phycoerythrin (PE)-conjugated CD11b, CD42a, CD49d and fluorescein isothiocyanate (FITC)-labelled CD14 antibody; FITC-and PE-labelled isotype-specific mAbs served as controls. Each antibody was from a single lot. Cell suspensions were incubated in the dark with saturating amounts of antibodies for 30 min at 4°C, washed and resuspended in 1% PF in PBS. Samples were stored in the dark at 4°C until they could be read (< 2 days). Samples were run through a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems) and at least 13 000 events were measured. The instrument settings were the same for all measurements and setting stability was regularly checked by fluorescent beads (Calibrite; Becton Dickinson Immunocytometry Systems). Data were transferred to IBM format using Consort 30 to IBM-PC Data TRANSFER (Becton Dickinson Immunocytometry Systems) and analysed using WinMDI software (Scripps Research Institute; http://www.facs.scripps.edu). Granulocytes were distinguished from other leucocytes by the combination of forward-and sidescattered laser light, monocytes were distinguished by CD14 expression and leucocyte-platelet complexes were distinguished by labelling with platelet-specific CD42a antibody. The relative cell surface antigen level was expressed as mean fluorescence intensity units, calculated by subtracting non-specific fluorescence, using a linear scale.
Statistical analysis
Results are presented as the meanϮSEM (meanϮSD for kinetic studies). The variables from each group (patients with and without restenosis) were analysed separately using Student's t-test for independent samples. Linear regression analysis was used to compare measurements of monocyte and granulocyte surface CD11b fluorescence intensity and the number of monocyte-and granulocyte-platelet complexes.
RESULTS
Clinical and angiographic results
The study population consisted of 24 patients, all male. The angioplasty procedure was successful in all patients and no significant complications occurred. None of the patients had early clinical events. Angiographic follow up was obtained and restenosis (diameter stenosis > 50%) was revealed in 10 patients. Table 1 summarizes the main clinical and angiographic characteristics of the patients, obtained before PTCA (subsequently, patients were divided into two groups according to the results of the control angiography). By the time of expiry of the follow-up period, 90% of patients with restenosis had effort angina. None of the patients had de novo-formed coronary lesions (with diameter stenosis > 50%) and symptoms of cardiac failure.
Dynamics of leucocyte surface antigen expression and leucocyte-platelet complex formation during activation in whole blood
The dynamics of monocyte surface expression of integrins Mac-1, VLA-4 (evaluated with specific antibodies against their respective ␣-subunits CD11b and CD49d) and the LPS-binding molecule CD14, as well as the time-course of monocyte-platelet interaction in whole blood were analysed using blood samples from three patients. As shown in Fig. 1 , monocyte surface exposure of Mac-1 integrin molecules significantly increased during incubation of blood with LPS and reached maximal values within 2 h. The effect of LPS on monocyte CD14 expression ( Fig. 1 ) was analogous to that of Mac-1 and is in agreement with previous data indicating a two-fold upregulation of CD14 that peaked between 1 and 3 h after LPS addition to blood. 18 Although we observed some monocyte-platelet association after blood storage on ice, incubation of blood with LPS elicited a significant increase in the number of plateletbearing monocytes (Fig. 1) . Surface VLA-4 integrin expression by monocytes was not upregulated and remained at the same level at all time points.
In our model of whole blood stimulation increases in granulocyte Mac-1 expression and the proportion of granulocytes associated with platelets were similar to observations made for monocytes (data not shown). Accordingly, all further measurements were performed under standard experimental conditions of storage of blood on ice for 1 h followed by a 2 h incubation with LPS (1 g/mL) at 37°C.
Surface Mac-1, VLA-4 and CD14 expression by activated monocytes
We determined that, after LPS activation of whole blood, monocyte expression of Mac-1 and VLA-4 was significantly higher for patients with restenosis than patients without restenosis (fluorescence intensities 1425 Ϯ 76 vs 1195 Ϯ 71 and 87 Ϯ 7 vs 65 Ϯ 6 for Mac-1 and VLA-4, respectively; all P < 0. 
Monocyte-platelet interactions
The number of monocyte-platelet complexes formed after LPS activation in whole blood was calculated as the percentage of CD42a-positive cells among CD14-expressing cells. As shown in Fig. 3 , the quantity of monocyte-platelet complexes was significantly higher for patients with restenosis than patients without restenosis (47 Ϯ 4 vs 29 Ϯ 3%, respectively; P < 0.05).
Granulocyte Mac-1 expression and granulocyte-platelet interactions
Surface expression of Mac-1 by granulocytes and the number of granulocyte-platelet complexes after activation in whole blood were also estimated. We found correlations between granulocyte and monocyte Mac-1 expression (r = 0.77) and between the quantities of granulocyte-platelet and monocyte-platelet complexes (r = 0.75). However, the measured parameters for granulocytes did not differ significantly between patients with and without restenosis (fluorescence intensities of 1126 Ϯ 106 vs 1050 Ϯ 72 and 
DISCUSSION
The present study has demonstrated that both monocyte Mac-1 and VLA-4 integrin expression and the propensity to form monocyte-platelet aggregates are altered in patients who develop postangioplasty restenosis.
Monocyte accumulation in the injured vessel is a key event in the initiation of inflammatory reactions that can lead to neointimal hyperplasia. Monocytic integrins Mac-1 and VLA-4 seem to be principal participants in monocyte recruitment to inflamed areas. Mac-1, a member of leucocyte-restricted ␤2-integrins, directly facilitates cell adhesion and transmigration at sites of fibrin(ogen) and platelet deposition. 19 Blockade of Mac-1 with antibodies has been shown to reduce neointimal thickening in animal models of angioplasty or stent implantation. 15 In Mac-1-deficient mice, an impaired transplatelet leucocyte migration, together with diminished neointimal formation after mechanical artery injury, have been observed. 20 Clinical studies have shown that Mac-1 expression on monocytes and granulocytes is increased locally and systemically after PTCA and that the magnitude of Mac-1 upregulation was higher in patients with subsequent clinical events. 8, 9 Known ligands of ␤1-integrin VLA-4 include matrix protein fibronectin and vascular cell adhesion molecule (VCAM)-1 adhesion molecules expressed on activated endothelial and smooth muscle cells. [21] [22] [23] Thus, VLA-4 can be used by monocytes for further invasion within an injured arterial wall. In endarterectomized baboons, anti-VLA-4 antibody has been shown to reduce the number of intimal monocytes/macrophages and neointimal thickening.
14 Here, we demonstrate, for the first time, that an increased monocyte surface VLA-4 expression may be characteristic of patients with restenosis. This observation provides the first evidence that, like Mac-1, VLA-4-mediated monocyte interactions with other cell types and matrix may also be important in the pathogenesis of restenosis in humans.
Our 'whole blood' model has allowed us to simultaneously evaluate the total number of Mac-1 and VLA-4 molecules participating in cell adhesion at sites of acute inflammation or vessel wall injury. It is well established that the majority of Mac-1 integrin molecules in resting monocytes are stored within intracellular compartments. Upon activation, monocytes rapidly transport Mac-1 receptors to the cell surface membrane, thus ensuring firm adhesion to specific ligands. 24 This explains the significant increase of surface Mac-1 exposure after LPS stimulation of monocytes in vitro. In contrast, the number of VLA-4 molecules was not upregulated by LPS. This finding is in accordance with previous observations indicating that VLA-4-dependent adhesion does not require cell activation and is principally mediated by affinity changes in the pre-existing molecules. 25 The appearance of heterophilic leucocyte-platelet aggregates in peripheral blood is indicative of a pro-inflammatory and prothrombotic status and is characteristic of patients with acute coronary syndromes, cardiopulmonary bypass and peripheral vascular disease. 26 It has been reported that PTCA-induced leucocyte-platelet complex formation was more pronounced in those patients who experienced late clinical events. 8 Leucocyte adhesion to platelets has important consequences. It can trigger leucocyte migration at the sites of vessel injury through the deposed platelet layer. 19 Moreover, the interaction between monocytes and platelets may result in modification of monocyte function, such as induction of tissue factor in monocytes. 27 The formation of monocyte-platelet aggregates is a complex process that involves several types of monocyte-and plateletadhesion receptors. Although in the present study we did not investigate the mechanism of monocyte-platelet association, we consider that it may result from gradual platelet and monocyte activation. Blood cooling has been shown to activate platelets and promote platelet aggregation 28 and, indeed, we observed some platelet-bearing monocytes after blood storage on ice. Stimulation of monocytes by subsequent incubation of blood with LPS at 37°C leads to further monocyte-platelet association. Thus, our data demonstrating an increased propensity for the formation of monocyte-platelet complexes in patients with restenosis compared with patients without restenosis may reflect monocyte and platelet hyperreactivity in the former group. Platelet hyperreactivity has already been observed in other models of platelet activation, with the alteration in platelet function being evident both before PTCA and 1-4 years after the procedure. 29, 30 Using the in vitro activation model described herein, we have found that for any given individual, both the expression of surface antigens on monocytes and the number of monocyte-platelet complexes are preserved at a constant level (CV < 10%) over a period of at least several (2-3) months (TI Arefieva et al., unpubl. obs., 2000), possibly reflecting an intrinsic reactivity level for each individual. For the present study, we have enrolled patients with analogous baseline characteristics. None of the patients presented with established clinical factors that could increase the likelihood of developing restenosis (acute coronary syndromes or a small diameter of the damaged vessel). Therefore, we speculate that restenosis may, at least in part, be associated with increased monocyte and platelet 'reactivity', as revealed for the restenotic group in the present study. Future investigations are aimed at establishing whether the measurement of these parameters may be of assistance in identifying patients prone to restenosis after PTCA or stenting. Fig. 3 Monocyte-platelet complex formation in whole blood in patients with (ᮀ) and without () restenosis. *P < 0.05 between the two patient groups.
